SOLIFENACIN IN THE TREATMENT OF OVERACTIVE BLADDER: RESULTS OF A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
- Authors: Ibinayeva I.S1, Apolikhina I.A1, Makhmedzhanova F.N1, Muslimova S.Z1
-
Affiliations:
- Issue: No 5 (2012)
- Pages: 24-29
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279583
- ID: 279583
Cite item
Open Access
Access granted
Abstract
The article presents the results of the evaluation of clinical efficacy and safety of the M-cholinoblocker solifenacin in the treatment of symptoms of overactive bladder (OAB). The study included 24 women aged from 47 to 69 years with symptoms of OAB lasting more than 3 months. It is shown that solifenacin at a dose of 5 mg reduces the quality of urinary urgency, improves the condition according to assessment of degree of discomfort due to symptoms of the OAB, treatment satisfaction and condition of the bladder.
Keywords
Full Text
About the authors
I. S Ibinayeva
I. A Apolikhina
Email: ncagp@bk.ru
F. N Makhmedzhanova
S. Z Muslimova
References
- Abrams P., Cardozo L., Fall M. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21:167-78.
- Abrams P., Artibani W., Cardozo L., Dmochowski R., van Kerrebroeck P., Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2006; 25:293-94.
- Payne C. K., Kelleher C. Redefining response in overactive bladder syndrome. BJU Int 2007; 99:101-6.
- Lesch K. P., Merschdorf U. Impulsivity, aggression, and serotonin: a molecular psychobiological perspective. Behav Sci Law 2000; 18:581-604.
- Steers W. Overactive bladder (OAB): What we thought we knew and what we know today. Urol Suppl 2002; 1:3-10.
- Artibani W. Outcomes in overactive bladder treatment: patient perception - a key to success. Eur Urol Suppl 2007; 6:17-22.
- Schagen van Leeuwen J. H., Castro R., Busse M., Bemelmans B. L. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006; 50:440-52.
- Chapple C. R., Artibani W., Cardozo L. D. et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005; 95:335-40.
- Chapple C. R., Martinez-Garcia R., Selvaggi L. et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48:464-70.
Supplementary files
